ROSE Stock Overview
Manufactures and sells veterinary products in Argentina. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Instituto Rosenbusch S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AR$98.00 |
| 52 Week High | AR$125.00 |
| 52 Week Low | AR$82.00 |
| Beta | 0.26 |
| 1 Month Change | -18.33% |
| 3 Month Change | -15.33% |
| 1 Year Change | 9.99% |
| 3 Year Change | 811.63% |
| 5 Year Change | 2,127.27% |
| Change since IPO | 31,324.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| ROSE | AR Pharmaceuticals | AR Market | |
|---|---|---|---|
| 7D | 0% | 2.8% | 4.4% |
| 1Y | 10.0% | -21.3% | 83.5% |
Return vs Industry: ROSE exceeded the AR Pharmaceuticals industry which returned -21.3% over the past year.
Return vs Market: ROSE underperformed the AR Market which returned 81.9% over the past year.
Price Volatility
| ROSE volatility | |
|---|---|
| ROSE Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in AR Market | 9.2% |
| 10% least volatile stocks in AR Market | 5.1% |
Stable Share Price: ROSE has not had significant price volatility in the past 3 months compared to the AR market.
Volatility Over Time: ROSE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | n/a | Rodolfo Martín Balestrini | www.rosenbusch.com |
Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious keratoconjunctivitis. It also provides pharmaceutical products, such as external and internal antiparasitics, endectocides, antimicotics-bacteriostatics, injectable antibiotics, antimastitics, and other chemotherapics, as well as vitamins and minerals.
Instituto Rosenbusch S.A. Fundamentals Summary
| ROSE fundamental statistics | |
|---|---|
| Market cap | AR$4.17b |
| Earnings (TTM) | AR$1.00b |
| Revenue (TTM) | AR$5.08b |
4.2x
P/E Ratio0.8x
P/S RatioIs ROSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROSE income statement (TTM) | |
|---|---|
| Revenue | AR$5.08b |
| Cost of Revenue | AR$2.91b |
| Gross Profit | AR$2.17b |
| Other Expenses | AR$1.16b |
| Earnings | AR$1.00b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 23.53 |
| Gross Margin | 42.64% |
| Net Profit Margin | 19.72% |
| Debt/Equity Ratio | 35.9% |
How did ROSE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 04:49 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Instituto Rosenbusch S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.